Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Animal models of prediabetes (Pre‐DM) are essential for studying metabolic disease and testing therapies, yet high‐fat diet (HFD) and HFD‐plus‐streptozotocin (STZ) protocols vary in feeding duration, STZ dose, and diagnostic criteria and rarely account for sex.
Min Xu +7 more
wiley +1 more source
Correspondence to editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis” [PDF]
Clinical and Molecular HepatologyJonggi Choi, Raymond T. Chung
doaj +1 more source
Chronic infection and metabolic stress: a converging axis driving hypertension and metabolic dysfunction-associated steatotic liver disease outcomes. [PDF]
Am J HypertensKountouras J +4 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Materials and Methods Data were analysed from two randomised, double‐blind, placebo‐controlled phase 2 trials.
Giacomo Ruotolo +13 more
wiley +1 more source
Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Correspondence to letter to the editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease” [PDF]
Clinical and Molecular HepatologyEileen L. Yoon +5 more
doaj +1 more source
Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou +5 more
wiley +1 more source
Metabolic dysfunction-associated steatotic liver disease predicts graft failure in kidney transplant recipients. [PDF]
Clin Kidney JLee K +7 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake +14 more
wiley +1 more source
Cognitive dysfunction in MASLD is linked to platelet activation. [PDF]
Front NeurosciChen J, Cheng C, Wang H, Yu T.
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background Genetic clusters related to Type 2 diabetes (T2D) have differential impact on cardiovascular diseases (CVDs), although the underlying mechanisms, such as proteomic perturbation, remain unexplored. We conducted a network Mendelian randomisation (MR) study to identify proteomic mediators linking T2D genetic clusters and CVDs.
Shuang Liao +4 more
wiley +1 more source